Study of VTRU200 for blood cancers and advanced solid tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug called VTRU200 for people with several types of blood cancers or advanced solid tumors that have not responded to standard treatment. The goal is to see if the drug is safe and effective, and it might offer a new option when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 6 months old, and the study includes adults and children.
- You must have one of these cancers: acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma (DLBCL) after CAR-T treatment, or an advanced solid tumor.
- Your cancer must have come back or not improved after previous treatment.
- If you have DLBCL, you must have already tried CAR-T therapy and it did not work.
- You should be in reasonably good health overall, able to do light activities.
- You cannot have certain heart, lung, or liver problems, active infections, or have had a recent stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.